Our research group utilizes cutting-edge technologies to analyze antimicrobial immune responses and develop new, highly effective anti-infective therapies and vaccines. This includes advanced methods of molecular genetic virus diagnostics, the development of modern, fully or partially synthetic modular vaccines, and the investigation and isolation of human monoclonal antibodies for innovative anti-infective strategies, such as antibody-drug conjugates.
Innovation and clinical translation with direct patient benefits are at the core of our mission. Public engagement and community involvement are crucial for successful innovation and progress towards effective prevention and treatment of infectious diseases, and these principles are firmly embedded in our work program.
